We are live on ! Find out more
CELGZ

Celgene Corporation Contingent Value Rights

Delisted

CELGZ was delisted on the 29th of November, 2019.

0 hedge funds and large institutions have $0 invested in Celgene Corporation Contingent Value Rights in 2019 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 240 (-24)

100% less capital invested

Capital invested by funds: $218K → $0 (-$218K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 24

Holders
Holders Change
-24
Holders Change %
-100%
% of All Funds
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
24
Calls
Puts
Net Calls
Net Calls Change

CELGZ Hedge Fund Activity: Q4 2019 in Review

0 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Celgene Corporation Contingent Value Rights (CELGZ) for Q4 2019, worth a combined $0 — down 100% from $218K a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of CELGZ and 0 opened new positions — a net loss of 24 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Davenport & Co, exiting entirely with an estimated $70K sold.

  • 0 institutional investors held Celgene Corporation Contingent Value Rights (CELGZ) as of Q4 2019, down from 24 in Q3 2019.
  • Funds reported $0 of Celgene Corporation Contingent Value Rights stock for Q4 2019, down 100% quarter-over-quarter.
  • 0 funds opened new Celgene Corporation Contingent Value Rights positions in Q4 2019 and 24 closed out, a net change of -24 holders.
  • The largest Celgene Corporation Contingent Value Rights seller in Q4 2019 was Davenport & Co, an estimated $70K sold.

Based on aggregated 13F filings for Q4 2019.